AMGEN
Denosumab
Phase 2 Study Published
Investigational Therapy Denosumab Increased Bone Mineral Density with Twice-Yearly Dosing — One Year Data Published in New England Journal of Medicine
Amgen announced publication of Phase 2 data demonstrating twice-yearly injections of denosumab, a RANK Ligand inhibitor, significantly increased bone mineral density in the total hip, lumbar spine, distal 1/3 radius and total body compared to placebo.